Can-Fite BioPharma Ltd. (CANF)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 300K 600K 900K FY21: 853K FY22: 810K FY23: 743K FY24: 674K FY25: 405K FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-15M -10M -5M 0 5M 10M 15M FY21: -12.8M FY22: -10.1M FY23: -8.2M FY24: -8.1M FY25: -9.9M FY21 FY22 FY23 FY24 FY25

Net Income Annual

-15M -10M -5M 0 5M 10M 15M FY21: -12.6M FY22: -10.2M FY23: -7.6M FY24: -7.9M FY25: -9.8M FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

-12M -8M -4M 0 4M 8M 12M FY21: -9.9M FY22: -10.8M FY23: -8.4M FY24: -7.6M FY25: -8.9M FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-12M -8M -4M 0 4M 8M 12M FY21: -9.9M FY22: -10.8M FY23: -8.4M FY24: -7.6M FY25: -9M FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 300M 600M 900M FY21: 553.1M FY22: 815.7M FY23: 426.1K FY24: 725.3K FY25: 1.6M FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.